Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Significant Increase in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 8,600 shares, an increase of 230.8% from the December 15th total of 2,600 shares. Based on an average daily trading volume, of 362,400 shares, the short-interest ratio is currently 0.0 days.

Oncotelic Therapeutics Stock Up 1.2 %

Shares of OTLC traded up $0.00 during midday trading on Thursday, hitting $0.03. The company had a trading volume of 3,011 shares, compared to its average volume of 217,291. The stock has a market cap of $14.14 million, a price-to-earnings ratio of -3.48 and a beta of -0.27. The company’s 50 day moving average price is $0.03 and its 200 day moving average price is $0.03. The company has a quick ratio of 0.01, a current ratio of 0.01 and a debt-to-equity ratio of 0.28. Oncotelic Therapeutics has a 52 week low of $0.02 and a 52 week high of $0.05.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.